These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16999950)

  • 1. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.
    Kassai A; Illyés L; Mirdamadi HZ; Seres I; Kalmár T; Audikovszky M; Paragh G
    Clin Biochem; 2007 Jan; 40(1-2):1-5. PubMed ID: 16999950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
    Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
    Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals.
    Bajnok L; Seres I; Varga Z; Jeges S; Peti A; Karanyi Z; Juhasz A; Csongradi E; Mezosi E; Nagy EV; Paragh G
    Metabolism; 2007 Nov; 56(11):1542-9. PubMed ID: 17950106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer.
    Mihajlovic M; Gojkovic T; Vladimirov S; Miljkovic M; Stefanovic A; Vekic J; Zeljkovic D; Trifunovic B; Kotur-Stevuljevic J; Spasojevic-Kalimanovska V; Zeljkovic A
    Clin Biochem; 2019 Jan; 63():32-38. PubMed ID: 30500525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H; Pahl MV; Elahimehr R; Vaziri ND
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure.
    Martinelli AEM; Maranhão RC; Carvalho PO; Freitas FR; Silva BMO; Curiati MNC; Kalil Filho R; Pereira-Barretto AC
    Lipids Health Dis; 2018 Oct; 17(1):242. PubMed ID: 30342531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
    Briand F; Magot T; Krempf M; Nguyen P; Ouguerram K
    Eur J Clin Invest; 2006 Apr; 36(4):224-30. PubMed ID: 16620283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase activities in hispanic and anglo postmenopausal women: associations with total and regional body fat.
    Greaves KA; Going SB; Fernandez ML; Milliken LA; Lohman TG; Bassford T; McNamara DJ
    Metabolism; 2003 Mar; 52(3):282-9. PubMed ID: 12647264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
    Kappelle PJ; de Boer JF; Perton FG; Annema W; de Vries R; Dullaart RP; Tietge UJ
    Eur J Clin Invest; 2012 May; 42(5):487-95. PubMed ID: 21955281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
    Kural BV; Orem C; Uydu HA; Alver A; Orem A
    Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
    Okamoto H; Miyai A; Sasase T; Furukawa N; Matsushita M; Nakano T; Nakajima K
    Clin Chim Acta; 2007 Jan; 375(1-2):92-8. PubMed ID: 16859664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.
    Zhang B; Fan P; Shimoji E; Xu H; Takeuchi K; Bian C; Saku K
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1910-5. PubMed ID: 15331428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.